What does Starpharma do?
What does Starpharma do?
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP® drug delivery and VivaGel®.
What is Lactin V?
Osel’s LACTIN-V is a live biotherapeutic product addressing women’s health disorders. LACTIN-V is under IND for preventing BV and rUTI. It contains Lactobacillus crispatus CTV-05, a single strain of hydrogen peroxide-producing vaginal Lactobacillus that is part of the natural vaginal microbiome of many healthy women.
Is strides a good company?
Strides Pharma is rated 4.1 out of 5, based on 654 reviews by employees on AmbitionBox. Strides Pharma is known for Skill development which is rated at the top and given a rating of 4.0. However, Job Security is rated the lowest at 3.5 and can be improved.
Will strides Pharma share go up?
Pharma stocks in general have seen a sharp sell-off in the last few months. In fact, stocks like Aurobindo Pharma have lost almost 30 to 35% from 52-week highs. Even Strides Pharma Science has fallen sharply….Strides Pharma stock has halved from 52-week highs.
|Current market price||52-week high||Fall|
|Rs 455||Rs 947||52.00%|
Can you live with BV?
Aside from having some uncomfortable symptoms, BV doesn’t usually cause any serious health problems for most healthy people.
Who is Starpharma Holdings Limited?
Starpharma Holdings Limited is a world leader in the development of dendrimer products for pharmaceutical, life-science and other applications. Starpharma’s women’s health product – VivaGel ® BV is based on SPL7013, astodrimer sodium, a proprietary dendrimer.
What happens when multiple insiders buy Starpharma shares?
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase… Starpharma Holdings Limited ( ASX:SPL ) shareholders have seen the share price descend 13% over the month. But the… © 2022 Yahoo. All rights reserved.
When did Starpharma report its half-year results?
Starpharma today released its interim report and financial results for the half-year ended 31 December 2019. Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its interim report and financial results for the half-year ended 31 December 2018.
What are Starpharma’s DEP® partnerships?
DEP ® partnerships include oncology programs with AstraZeneca, with Merck & Co., Inc., in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma’s partnered DEP ® programs have the potential to generate significant future milestones and royalties.